商业协议预计在 18 个月试点后，五年内价值约 450 万美元； 服务将通过 Beilinson NEXT，即 Beilinson 的虚拟医院进行部署
, /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM)，全球领先的连接家庭超声技术公司，今天宣布与以色列最大的健康维护组织 Clalit Health Services 达成一项额外的战略商业协议，提供 Pulsenmore FC，这是一种为接受生育护理的女性（IVF 和 生育保存）设计的新型家庭超声解决方案，旨在进行 远程卵泡监测。该协议预计在 18 个月试点后，五年内价值约 450 万美元。双方预计将在接下来的几周内开始扩大实施。
<img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg"/>
根据协议，Pulsenmore 和 Clalit 将建立一个通过 Beilinson NEXT 运营的端到端临床服务，使符合条件的患者能够在家中进行卵泡监测扫描，并获得实时在线指导和专业临床监督。该协议允许 Pulsenmore 和 Clalit 直接向患者推广 Pulsenmore FC。
Pulsenmore 此前在 2025 年 6 月报告了在 Beilinson Medical Center 进行的受控临床研究结果，显示出良好的安全性，家庭测量与临床评估之间高度一致。
生育治疗通常需要频繁的临床阴道超声扫描和多次就诊，这会干扰日常生活。Pulsenmore FC 旨在提供另一种方式，使符合条件的患者能够使用 Pulsenmore FC（一种患者操作的超声设备）和移动应用中的逐步指导，在家中完成卵泡监测扫描。扫描数据安全地传输到 Beilinson NEXT 护理团队进行远程解读和临床监督，支持卵泡发育和子宫内膜厚度的监测，以准确把握治疗中的关键时刻，包括触发注射和取卵，同时帮助减少在 IVF 和生育保存周期中多次到访临床的需要。
&#34;我们相信这项协议代表了生育护理交付方式的全球突破，&#34; Pulsenmore 的首席执行官兼创始人 Elazar Sonnenschein 博士 表示。&#34;我们正在启用一种新的护理模式，尊重患者的时间、隐私和日常生活，同时保持临床监督。我们感谢 Clalit 的领导和勇气，为 Beilinson Medical Center 和 Beilinson NEXT 开辟新天地。他们正在为家庭提供专业、富有同情心和连接的护理设定新的标准。&#34;
Clalit 的首席执行官 Eytan Wirtheim 博士 欢迎协议的签署以及第一阶段的启动——针对有限女性群体的试点实施阶段。
根据 Wirtheim 的说法，&#34;这项服务与 Clalit 的新战略愿景无缝契合，'医学已经离开了建筑'：任何可以在患者舒适和宁静的家中提供的医疗服务，而不是要求患者到医院诊所就诊的服务，都将以这种方式提供——前提是能够以与医院环境相同的质量水平提供。我相信，一旦我们达到向公众提供这项服务的阶段，每位女性和每对夫妇在经历生育治疗时——无论是情感上还是身体上都复杂——都会欣赏 Clalit 的新服务。对于选择与我们继续接受服务的女性和夫妇，我们将自豪地提供一种创新的、全球领先的混合服务，使生活更轻松，即使在医疗过程中。&#34;
Pulsenmore 还向 Clalit 提供 Pulsenmore ES，其医生监督的家庭产前超声解决方案，该方案最近获得了 FDA De Novo 授权。在 2024 年 10 月，Pulsenmore 与 Clalit 签署了一项具有约束力的协议，未来五年内提供额外的 25,000 台 Pulsenmore ES 设备，并通过 Pulsenmore 的硬件、安全图像传输和临床审查工作流程支持 Clalit 在以色列的护理路径。
*Pulsenmore FC（卵泡监测）已获得以色列的商业使用批准。
关于 Pulsenmore
Pulsenmore Ltd.致力于通过开发家庭使用的超声技术来彻底改变母婴健康，连接母亲和医疗提供者。通过利用先进的成像和远程医疗，Pulsenmore 使护理以患者为中心，扩大了获取渠道并改善了护理的连续性。有关更多信息，请访问 www.pulsenmore.com
关于 Clalit Health Services
Clalit Health Services 是以色列最大的健康维护组织（HMO），在全国服务近五百万会员，并运营一个综合的社区诊所和医院网络。Clalit 是一个公共非营利组织，拥有并运营 14 家医院，以及广泛的初级和专科护理服务网络。
关于 Beilinson NEXT 虚拟医院
Beilinson NEXT 是 Beilinson Medical Center 的虚拟医院，与 Clalit Health Services 合作建立。其使命是向患者远程提供先进的专业护理，将医院的专业知识扩展到物理医院环境之外，以支持获取、护理的连续性和临床监督，无论患者身在何处。
前瞻性声明
本新闻稿包含前瞻性声明。特别是，使用诸如 “可能”、“寻求”、“将”、“考虑”、“可能”、“假设”、“估计”、“期望”、“预期”、“打算”、“相信”、“思考”、“不相信”、“目标”、“目的”、“由于”、“预测”、“计划”、“项目”、“继续”、“潜在”、“定位”、“指导”、“目标”、“展望”、“趋势”、“未来”、“可以”、“会”、“应该”、“目标”、“在轨” 等词语或其否定形式或变体，以及类似术语和具有类似重要性的词语，通常涉及未来或前瞻性声明。这些前瞻性声明包括但不限于与协议潜在价值、Pulsenmore FC 的市场机会以及市场增长潜力相关的声明。前瞻性声明反映了 Pulsenmore 对未来事件或财务表现的当前看法、计划或期望。它们本质上受到重大商业、经济、竞争及其他风险、不确定性和偶发事件的影响。前瞻性声明基于 Pulsenmore 当前的期望，并受到固有的不确定性、风险和假设的影响，这些因素难以预测，包括但不限于以下内容：公司缺乏运营历史；公司当前和未来的资本需求，以及公司相信其现有现金将足以在财务报表发布之日起一年以上资助其运营；公司制造、营销和销售其产品并产生收入的能力；公司维持与关键合作伙伴关系并与新合作伙伴建立关系的能力；公司维护或保护其美国及其他专利和其他知识产权有效性的能力；公司在新地点和新市场细分中推出和渗透市场的能力；公司留住关键高管成员和招聘额外人员的能力；公司维护和扩展知识产权的能力；对现行法律的解释和未来法律的通过；公司在现有和新市场中实现更大监管合规的能力；公司在计划的运营测试中实现关键绩效里程碑的能力；公司建立足够的销售、营销和分销渠道的能力；中东地区的安全、政治和经济不稳定可能对其业务造成损害；以及投资者对公司商业模式的接受程度。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向美国证券交易委员会（SEC）提交的报告，包括但不限于公司在 2025 年 12 月 29 日向 SEC 提交的 20-F 表格（SEC 文件编号 001-43033）中包含的风险、不确定性和其他因素。在本次或任何其他沟通中包含前瞻性声明不应被视为 Pulsenmore 或任何其他人对当前计划或期望将实现的陈述。前瞻性声明仅在作出之日有效，Pulsenmore 不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因，法律另有规定的除外。
投资者联系：
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com
图片 - https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg
来源：Pulsenmore Ltd.

PLSM

Pulsenmore Ltd. 与 Clalit Health Services 签署了一项战略商业协议，推出一项家庭卵泡监测服务，用于 IVF 和生育保存，价值约为 450 万美元，期限为五年。该服务将通过 Beilinson NEXT 运营，使符合条件的患者能够在家中进行扫描，并获得实时指导。此举旨在提高患者的便利性，同时保持临床监督，减少在诊所就诊的需求。两家公司对该服务对生育护理交付的潜在影响持乐观态度

Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month pilot; Service to be deployed via Beilinson NEXT, Beilinson's virtual hospital
<div class="lb-trans">商业协议预计在 18 个月试点后，五年内价值约 450 万美元； 服务将通过 Beilinson NEXT，即 Beilinson 的虚拟医院进行部署
</div>, /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a global leader in connected home ultrasound technology, today announced an additional strategic commercial agreement with Clalit Health Services, Israel's largest health maintenance organization (HMO), to supply Pulsenmore FC, a new at-home ultrasound solution designed for remote follicular monitoring in women undergoing fertility care ( IVF and fertility preservation). The agreement is potentially valued at approximately $ 4.5 million over five years following an 18 month pilot . The parties expect to begin ramp-up in the coming weeks.
<div class="lb-trans">, /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM)，全球领先的连接家庭超声技术公司，今天宣布与以色列最大的健康维护组织 Clalit Health Services 达成一项额外的战略商业协议，提供 Pulsenmore FC，这是一种为接受生育护理的女性（IVF 和 生育保存）设计的新型家庭超声解决方案，旨在进行 远程卵泡监测。该协议预计在 18 个月试点后，五年内价值约 450 万美元。双方预计将在接下来的几周内开始扩大实施。
</div><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg" alt="" original-src="https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg"/>
Under the agreement, Pulsenmore and Clalit will establish an end-to-end clinical service operated through Beilinson NEXT, Beilinson Medical Center's virtual hospital, enabling eligible patients to perform follicular monitoring scans from home with real-time online guidance and specialist clinical oversight. The agreement allows both Pulsenmore and Clalit to market Pulsenmore FC directly to patients.
<div class="lb-trans">根据协议，Pulsenmore 和 Clalit 将建立一个通过 Beilinson NEXT 运营的端到端临床服务，使符合条件的患者能够在家中进行卵泡监测扫描，并获得实时在线指导和专业临床监督。该协议允许 Pulsenmore 和 Clalit 直接向患者推广 Pulsenmore FC。
</div>Pulsenmore previously reported results in June 2025 from a controlled clinical study at Beilinson Medical Center that demonstrated a strong safety profile, with high concordance between at-home measurements and in-clinic assessments.
<div class="lb-trans">Pulsenmore 此前在 2025 年 6 月报告了在 Beilinson Medical Center 进行的受控临床研究结果，显示出良好的安全性，家庭测量与临床评估之间高度一致。
</div>Fertility treatment often requires frequent in-clinic transvaginal ultrasound scans and repeated visits that disrupt daily life. Pulsenmore FC is designed to offer another way, enabling eligible patients to complete follicular monitoring scans from home using the Pulsenmore FC, a patient-operated ultrasound device, and step-by-step guidance in a mobile app. Scan data are transmitted securely to the Beilinson NEXT care team for remote interpretation and clinical oversight, supporting monitoring of follicle development and endometrial thickness for accurate timing of key moments in treatment, including the trigger injection and egg retrieval, while helping reduce the need for repeated in-clinic visits during IVF and fertility preservation cycles.
<div class="lb-trans">生育治疗通常需要频繁的临床阴道超声扫描和多次就诊，这会干扰日常生活。Pulsenmore FC 旨在提供另一种方式，使符合条件的患者能够使用 Pulsenmore FC（一种患者操作的超声设备）和移动应用中的逐步指导，在家中完成卵泡监测扫描。扫描数据安全地传输到 Beilinson NEXT 护理团队进行远程解读和临床监督，支持卵泡发育和子宫内膜厚度的监测，以准确把握治疗中的关键时刻，包括触发注射和取卵，同时帮助减少在 IVF 和生育保存周期中多次到访临床的需要。
</div>&#34;We believe this agreement represents a global breakthrough in how fertility care can be delivered,&#34; said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. &#34;We are enabling a new model of care that respects patients' time, privacy, and daily lives, while maintaining clinical oversight. We're grateful to Clalit for their leadership and courage to break new ground for the Beilinson Medical Center and Beilinson NEXT. They are setting a new standard for professional, empathetic, and connected care from home.&#34;
<div class="lb-trans">&#34;我们相信这项协议代表了生育护理交付方式的全球突破，&#34; Pulsenmore 的首席执行官兼创始人 Elazar Sonnenschein 博士 表示。&#34;我们正在启用一种新的护理模式，尊重患者的时间、隐私和日常生活，同时保持临床监督。我们感谢 Clalit 的领导和勇气，为 Beilinson Medical Center 和 Beilinson NEXT 开辟新天地。他们正在为家庭提供专业、富有同情心和连接的护理设定新的标准。&#34;
</div>Clalit's CEO, Dr. Eytan Wirtheim welcomed the signing of the agreement and the launch of Phase I - the pilot implementation phase for a limited group of women.
<div class="lb-trans">Clalit 的首席执行官 Eytan Wirtheim 博士 欢迎协议的签署以及第一阶段的启动——针对有限女性群体的试点实施阶段。
</div>According to Wirtheim, &#34;This service fits seamlessly into Clalit's new strategic vision, under which 'Medicine has left the building': any medical service that can be provided to patients from the comfort and calm of their homes, instead of requiring visits to hospital clinics, will be offered in this way as well - provided it can be delivered at the same level of quality as in the hospital setting. I am confident that once we reach the stage of offering this service to the general public, every woman and every couple who will undergo fertility treatments - with all the emotional and physical complexity they entail - will come to appreciate Clalit's new service. For the women and couples who choose to receive the service with us going forward, we will be proud to provide an innovative, world-leading hybrid service that makes life easier, even during the medical process.&#34;
<div class="lb-trans">根据 Wirtheim 的说法，&#34;这项服务与 Clalit 的新战略愿景无缝契合，'医学已经离开了建筑'：任何可以在患者舒适和宁静的家中提供的医疗服务，而不是要求患者到医院诊所就诊的服务，都将以这种方式提供——前提是能够以与医院环境相同的质量水平提供。我相信，一旦我们达到向公众提供这项服务的阶段，每位女性和每对夫妇在经历生育治疗时——无论是情感上还是身体上都复杂——都会欣赏 Clalit 的新服务。对于选择与我们继续接受服务的女性和夫妇，我们将自豪地提供一种创新的、全球领先的混合服务，使生活更轻松，即使在医疗过程中。&#34;
</div>Pulsenmore also supplies Clalit with Pulsenmore ES , its physician-supervised home prenatal ultrasound solution, which has recently received FDA De Novo authorization. In October 2024, Pulsenmore signed a binding agreement with Clalit for an additional 25,000 Pulsenmore ES units over five years, supported by Pulsenmore's hardware, secure image transmission, and clinical review workflows across Clalit's care pathways in Israel.
<div class="lb-trans">Pulsenmore 还向 Clalit 提供 Pulsenmore ES，其医生监督的家庭产前超声解决方案，该方案最近获得了 FDA De Novo 授权。在 2024 年 10 月，Pulsenmore 与 Clalit 签署了一项具有约束力的协议，未来五年内提供额外的 25,000 台 Pulsenmore ES 设备，并通过 Pulsenmore 的硬件、安全图像传输和临床审查工作流程支持 Clalit 在以色列的护理路径。
</div>*Pulsenmore FC (follicular monitoring) is approved for commercial use in Israel.
<div class="lb-trans">*Pulsenmore FC（卵泡监测）已获得以色列的商业使用批准。
</div>About Pulsenmore
<div class="lb-trans">关于 Pulsenmore
</div>Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com
<div class="lb-trans">Pulsenmore Ltd.致力于通过开发家庭使用的超声技术来彻底改变母婴健康，连接母亲和医疗提供者。通过利用先进的成像和远程医疗，Pulsenmore 使护理以患者为中心，扩大了获取渠道并改善了护理的连续性。有关更多信息，请访问 www.pulsenmore.com
</div>About Clalit Health Services
<div class="lb-trans">关于 Clalit Health Services
</div>Clalit Health Services is Israel's largest health maintenance organization (HMO), serving close to five million members nationwide and operating an integrated network of community-based clinics and hospitals. Clalit is a public, nonprofit organization and owns and operates 14 hospitals alongside a broad national network of primary and specialty care services.
<div class="lb-trans">Clalit Health Services 是以色列最大的健康维护组织（HMO），在全国服务近五百万会员，并运营一个综合的社区诊所和医院网络。Clalit 是一个公共非营利组织，拥有并运营 14 家医院，以及广泛的初级和专科护理服务网络。
</div>About Beilinson NEXT Virtual Hospital
<div class="lb-trans">关于 Beilinson NEXT 虚拟医院
</div>Beilinson NEXT is Beilinson Medical Center's virtual hospital, built in partnership with Clalit Health Services. Its mission is to deliver advanced, specialist-level care to patients remotely, extending hospital expertise beyond the physical hospital setting to support access, continuity of care, and clinician oversight wherever patients are.
<div class="lb-trans">Beilinson NEXT 是 Beilinson Medical Center 的虚拟医院，与 Clalit Health Services 合作建立。其使命是向患者远程提供先进的专业护理，将医院的专业知识扩展到物理医院环境之外，以支持获取、护理的连续性和临床监督，无论患者身在何处。
</div>Forward-Looking Statements
<div class="lb-trans">前瞻性声明
</div>This press release contains forward-looking statements. In particular, statements using words such as &#34;may,&#34; &#34;seek,&#34; &#34;will,&#34; &#34;consider,&#34; &#34;likely,&#34; &#34;assume,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;believe,&#34; &#34;contemplate,&#34; &#34;do not believe,&#34; &#34;aim,&#34; &#34;goal,&#34; &#34;due,&#34; &#34;predict,&#34; &#34;plan,&#34; &#34;project,&#34; &#34;continue,&#34; &#34;potential,&#34; &#34;positioned,&#34; &#34;guidance,&#34; &#34;objective,&#34; &#34;outlook,&#34; &#34;trends,&#34; &#34;future,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;target,&#34; &#34;on track&#34; or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the potential value of the agreement, the market opportunity of Pulsenmore FC and the potential for market growth. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
<div class="lb-trans">本新闻稿包含前瞻性声明。特别是，使用诸如 “可能”、“寻求”、“将”、“考虑”、“可能”、“假设”、“估计”、“期望”、“预期”、“打算”、“相信”、“思考”、“不相信”、“目标”、“目的”、“由于”、“预测”、“计划”、“项目”、“继续”、“潜在”、“定位”、“指导”、“目标”、“展望”、“趋势”、“未来”、“可以”、“会”、“应该”、“目标”、“在轨” 等词语或其否定形式或变体，以及类似术语和具有类似重要性的词语，通常涉及未来或前瞻性声明。这些前瞻性声明包括但不限于与协议潜在价值、Pulsenmore FC 的市场机会以及市场增长潜力相关的声明。前瞻性声明反映了 Pulsenmore 对未来事件或财务表现的当前看法、计划或期望。它们本质上受到重大商业、经济、竞争及其他风险、不确定性和偶发事件的影响。前瞻性声明基于 Pulsenmore 当前的期望，并受到固有的不确定性、风险和假设的影响，这些因素难以预测，包括但不限于以下内容：公司缺乏运营历史；公司当前和未来的资本需求，以及公司相信其现有现金将足以在财务报表发布之日起一年以上资助其运营；公司制造、营销和销售其产品并产生收入的能力；公司维持与关键合作伙伴关系并与新合作伙伴建立关系的能力；公司维护或保护其美国及其他专利和其他知识产权有效性的能力；公司在新地点和新市场细分中推出和渗透市场的能力；公司留住关键高管成员和招聘额外人员的能力；公司维护和扩展知识产权的能力；对现行法律的解释和未来法律的通过；公司在现有和新市场中实现更大监管合规的能力；公司在计划的运营测试中实现关键绩效里程碑的能力；公司建立足够的销售、营销和分销渠道的能力；中东地区的安全、政治和经济不稳定可能对其业务造成损害；以及投资者对公司商业模式的接受程度。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向美国证券交易委员会（SEC）提交的报告，包括但不限于公司在 2025 年 12 月 29 日向 SEC 提交的 20-F 表格（SEC 文件编号 001-43033）中包含的风险、不确定性和其他因素。在本次或任何其他沟通中包含前瞻性声明不应被视为 Pulsenmore 或任何其他人对当前计划或期望将实现的陈述。前瞻性声明仅在作出之日有效，Pulsenmore 不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因，法律另有规定的除外。
</div>Investor Contact:
<div class="lb-trans">投资者联系：
</div>Miri Segal-Scharia
<div class="lb-trans">Miri Segal-Scharia
</div>MS-IR LLC
<div class="lb-trans">MS-IR LLC
</div>msegal@ms-ir.com
<div class="lb-trans">msegal@ms-ir.com
</div>Image - https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg
<div class="lb-trans">图片 - https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg
</div>SOURCE Pulsenmore Ltd.
<div class="lb-trans">来源：Pulsenmore Ltd.
</div>

Pulsenmore 与 Clalit 健康服务合作推出首个居家卵泡监测服务，适用于试管婴儿和生育保存 | PLSM 股票新闻